ALBT · Avalon Globocare Corp. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $1.33M | $3.58M | $1.20M | $1.39M | $1.38M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | $272.7K | $414.5K | $390.2K |
| R&D | - | $0 | $109.6K | $731.3K | $1.03M | $883.9K |
| SG&A | - | - | - | - | - | - |
| Total Operating Expenses | $7.98M | $1.07M | $1.02M | $9.07M | $9.25M | $12.84M |
| D&A | $94.4K | $177.9K | $211.7K | $330.7K | $311.8K | $314.8K |
| Operating Income | ($7.59M) | ($4.93M) | ($15.75M) | ($8.79M) | ($8.83M) | ($12.45M) |
| Interest Expense | $1.46M | $42.4K | $31.2K | $176.0K | - | - |
| Income Tax | - | - | - | - | - | - |
| Net Income | ($18.26M) | ($7.90M) | ($16.71M) | ($11.93M) | ($9.09M) | ($12.68M) |
| EPS - Basic | ($5.64) | ($8.44) | ($1.59) | ($1.07) | - | - |
| EPS - Diluted | ($5.64) | ($8.44) | ($1.59) | ($1.07) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $109.1K | $2.86M | $285.4K | $1.99M | $807.5K | $726.6K |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | $87.2K |
| Current Assets | $1.50M | $3.24M | $850.9K | $2.37M | $1.32M | $1.29M |
| Total Assets | $23.40M | $20.99M | $20.58M | $19.75M | $10.24M | $10.37M |
| Current Liabilities | $14.15M | $13.88M | $6.76M | $3.58M | $4.40M | $2.59M |
| Long-term Debt | - | - | - | - | $3.00M | - |
| Total Liabilities | $14.17M | $13.88M | $13.21M | $8.59M | $7.16M | $6.25M |
| Stockholders' Equity | $9.23M | $7.10M | $7.37M | $11.16M | $3.08M | $4.12M |
| Retained Earnings | ($105.93M) | ($87.67M) | ($79.77M) | ($63.06M) | ($51.13M) | ($42.04M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.67M) | ($4.97M) | ($6.50M) | ($7.04M) | ($5.02M) | ($7.55M) |
| Investing Cash Flow | ($100.0K) | ($100.0K) | ($22.2K) | ($9.05M) | ($68.1K) | ($169.2K) |
| Financing Cash Flow | $1.40M | $7.64M | $4.83M | $17.26M | $5.17M | $7.66M |
| CapEx | - | - | $22.2K | $17.5K | - | - |
| Free Cash Flow | - | - | ($6.53M) | ($7.05M) | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | 22.7% | 29.8% | 28.3% |
| Operating margin | - | -369.6% | -440.5% | -731.4% | -635.1% | -903.9% |
| EBITDA margin | - | -356.2% | -434.6% | -703.9% | -612.7% | -881.1% |
| Net margin | - | -592.7% | -467.2% | -992.4% | -653.5% | -920.3% |
| Free cash flow margin | - | - | -182.5% | -586.8% | - | - |
| FCF / Net income | - | - | 0.39 | 0.59 | - | - |
| R&D / Revenue | - | 0.0% | 3.1% | 60.8% | 73.7% | 64.2% |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -78.0% | -37.7% | -81.2% | -60.4% | -88.8% | -122.3% |
| Return on equity | -197.8% | -111.3% | -226.7% | -106.9% | -294.7% | -308.0% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.11 | 0.23 | 0.13 | 0.66 | 0.30 | 0.50 |
| Quick ratio | 0.11 | 0.23 | 0.13 | 0.66 | 0.30 | 0.50 |
| Cash ratio | 0.01 | 0.21 | 0.04 | 0.56 | 0.18 | 0.28 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | 0.97 | - |
| Debt / Assets | - | - | - | - | 0.29 | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -5.2x | -116.1x | -505.5x | -50.0x | - | - |
| Equity multiplier | 2.54 | 2.95 | 2.79 | 1.77 | 3.32 | 2.52 |
| Liabilities / Assets | 0.61 | 0.66 | 0.64 | 0.44 | 0.70 | 0.60 |
| Efficiency | ||||||
| Asset turnover | 0.00 | 0.06 | 0.17 | 0.06 | 0.14 | 0.13 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -100.0% | -62.7% | 197.5% | -13.6% | 1.0% | -10.9% |
| Revenue CAGR (3y) | - | -1.4% | 37.4% | -8.0% | -3.8% | 8.5% |
| Revenue CAGR (5y) | - | -2.9% | 18.0% | 2.2% | 17.7% | - |
| Gross profit growth (YoY) | - | - | - | -34.2% | 6.2% | 14.8% |
| Operating income growth (YoY) | -54.1% | 68.7% | -79.2% | 0.5% | 29.1% | 35.7% |
| Net income growth (YoY) | -131.1% | 52.7% | -40.0% | -31.2% | 28.3% | 29.8% |
| EPS growth (YoY) | 33.2% | -430.8% | -48.6% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 7.5% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 30.0% | -3.6% | -34.0% | 261.8% | -25.1% | -7.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Business segments
$1.33M totalReal Property Operations$1.33M · 100.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-4.96
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Services-Computer Programming Services
Comparing Avalon GloboCare Corp. against the 5 most active filers in the same SIC group.